Theriva Biologics Inc (FRA:SFY)
€ 0.227 -0.009 (-3.81%) Market Cap: 3.99 Mil Enterprise Value: -8.48 Mil PE Ratio: 0 PB Ratio: 0.14 GF Score: 33/100

Q4 2023 Theriva Biologics Inc Earnings Call Transcript

Mar 25, 2024 / 12:30PM GMT
Release Date Price: €0.45 (+1.35%)
Operator

And greetings, and welcome to the Theriva Biologics full year 2023 investor conference call.

At this time, all participants are in a listen only mode. As a reminder, this conference is being recorded. I would now like to turn the call over to your host Chris Calabrese with LifeSci Advisors. Thank you. You may begin.

Chris Calabrese LifeSci Advisors;IR

Thank you, operator, and good morning, everyone. Welcome to the Theriva Biologics full year 2023 investor conference call. Leading the call today will be Steven Shallcross, Chief Executive and Chief Financial Officer of Theriva Biologics; Dr. Medel, Qwest guy of General Director of the RevA biologics, European subsidiary, and Dr. Vince wager, Head of Corporate and Product Development of Spiriva biologics are also on the call and will be available to answer questions during the Q&A session.

The review Biologics issued a press release this morning, which provided operational highlights and included the financial results for the full year ending December 31, 2023. The press release can

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot